 |
Onmark Continues Expansion of Contract PortfolioDecember 01, 2009 |
|
|
|
|
New Additions Deliver Critical Cost Savings to Physician Members South San Francisco, Calif. – December 1, 2009 – Onmark, a leading group purchasing organization (GPO) and McKesson Specialty Care Solutions company, has enhanced its contract portfolio with three additional products. Onmark members now have the opportunity to purchase Eisai’s FRAGMIN®, AMAG Pharmaceuticals’ Feraheme™ and Baxter’s GAMMAGARD® Liquid at significant cost savings. The latest additions expand the diversity of Onmark’s pharmaceutical contract portfolio, which includes the majority of the most widely used chemotherapy, biologic and supportive care agents. In addition to contract savings, Onmark offers a robust suite of clinical tools, practice management resources and educational programs to help its members deliver efficient, cost-effective and high-quality patient care. "Decreasing reimbursement and the economic downturn have forced community-based practices to find new ways to save money while maintaining high patient care standards,” stated Bob Orzechowski, chief operating officer at Berks Hematology Oncology Associates in West Reading, Pennsylvania. “Onmark regularly brings us new savings by expanding its contract portfolio, which enables us to continue providing quality care to patients in our community."> Eisai Inc.’s FRAGMIN (dalteparin sodium injection) is a low–molecular-weight heparin (LMWH) that helps keep blood clots from forming or getting larger in patients who have undergone or are planning certain surgeries and/or when deep vein thrombosis (DVT) is a risk. FRAGMIN may also be used for extended treatment of symptomatic VTE (DVT and/or pulmonary embolism) to lower the chance of VTE recurring in patients with cancer. [1] AMAG Pharmaceuticals, Inc.’s, Feraheme (ferumoxytol) Injection for Intravenous (IV) use is indicated for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD).[2] GAMMAGARD Liquid therapy (immune globulin intravenous (human) is produced by Baxter and is a specially formulated 10% intravenous immunoglobulin (IVIG) therapy with demonstrated efficacy, viral safety and tolerability for children and adults with primary immunodeficiency.[3] "Community-based physicians are facing unprecedented economic headwinds," states Mike Cunningham, Pharm D, vice president and general manager of GPO & Information Services for McKesson Specialty Care Solutions. "Now more than ever, our members look to McKesson and Onmark for solutions to help them thrive from a clinical, financial and operational perspective. We will continue to leverage our strong relationships with manufacturers to negotiate new contracts and savings opportunities that support our members’ long-term success." About Onmark Onmark, a McKesson Specialty Care Solutions company, is a leading national group purchasing organization (GPO) for community-based practices with more than 3000 members representing over 4,800 physicians and in excess of $8 billion in annual drug purchases. Through strategic relationships with McKesson Corporation, pharmaceutical companies and industry experts, Onmark provides its members with access to a full portfolio of competitive contracts for pharmaceutical products and medical/surgical supplies, the most aggressive pricing available through McKesson, practice management resources, clinical tools and educational programs For information about the products, services and programs available to Onmark members, visit www.onmarkservices.com. About McKesson and McKesson Specialty Care Solutions [3] http://www.gammagardliquid.com/ FRAGMIN® is a registered trademark of Pfizer Health AB and is licensed to Eisai Inc. Feraheme™ is a trademark of AMAG Pharmaceuticals, Inc. GAMMAGARD® is a registered trademark of Baxter International, Inc.
PR ContactToni J. Eberhardt | 480-663-4108 | toni.eberhardt@mckesson.com |
||||
